No Data
No Data
Tourmaline Bio, Inc. Announces Virtual Investor Day to Discuss Development of Pacibekitug on December 10, 2024
H.C. Wainwright Maintains Tourmaline Bio(TRML.US) With Buy Rating, Raises Target Price to $49
Tourmaline Bio Price Target Raised to $49 From $48 at H.C. Wainwright
Tourmaline Bio's Promising Clinical Developments and Financial Stability Underpin Buy Rating
Express News | Tourmaline Bio Inc Files for Mixed Shelf of up to $350 Mln - SEC Filing
Talaris Therapeutics GAAP EPS of -$0.78 Beats by $0.05
No Data
No Data
Trytosaveabit : Larry Fink is a terrible awful person! Sad part it’s hard to trade any ticker that he don’t have a part of! He has been on a buying spree! I’ve seen at least 25 in last 24 hours! Prolly more that he has been buying!